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Summary Oestrogen and progesterone receptor assays were performed in 286 women with primary breast
cancer, and the patient group was followed up for a minimum of 24 months. Of the 263 patients belonging to
clinical stages I-III and serving as the population used for calculation of disease-free interval only 1.9%
received postoperative endocrine treatment and 6.5% chemotherapy.
No significant relationship between the presence or concentrations of oestrogen or progesterone receptor
and the disease-free interval was observed. It is therefore possible that the positive relationship between these
variables reported in some investigations reflects an influence by adjuvant endocrine measures.
In breast carcinoma, oestrogen receptor (ER)
positivity is considered to be a good prognostic sign
because ER-positive breast cancer patients have
been reported to have a longer disease-free interval
(Furmanski et al., 1980; Gapinski et al., 1980;
Hartveit et al., 1980; Hahnel et al., 1979; Knight et
al., 1977; Leake et al., 1981; Lippman et al., 1980;
Westerberg et al., 1980). Recently, determination of
progesterone receptor (PR) has been reported to
give similar or even more accurate information
(Saez et al., 1983; Clark et al., 1983). However,
contrary data is available for the relations between
ER (Hilf et al., 1980; Kinne et al., 1981 and Howat
et al., 1983) and PR (Griffiths et al., 1983; Howat
et al., 1983) status and the disease-free interval in
breast cancer. There are some possible explanations
for the conflicts in these studies. ER assays have
not always been performed from primary tumours
and specimens from metastatic sites are
retrospective in nature and discordance in receptor
status in sequential specimens has been reported to
be 23% for ER and 30% for PR assays (Harland et
al., 1983). In addition on some studies a large part
of the patients have received some form of
chemotherapeutic or endocrine treatment. Some
reports omit information regarding these two
important factors. Since the efficacy of adjuvant
endocrine treatment has been shown to be related
to the presence of ER in the tumour tissue (Fisher
et al., 1981), this kind of treatment certainly
complicates the evaluation of the relationship
between receptor status and the disease-free
interval.
In this article, we will present our data
concerning the prognostic value of the presence and
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concentrations of oestrogen and progesterone
receptors in primary tumours of 263 women with
stage I-III breast carcinoma, operated mainly with
the modified radical mastectomy and followed up
meticulously in a breast clinic. Only 8.3% of these
patients received postoperative chemotherapeutic or
endocrine treatment. The minimum follow-up
period was 24 months, the mean 41 months.
Materials and methods
Patients and treatments
During the years 1977-1979 determinations of ER
and PR concentrations were performed on the
tumours of 286 women with primary breast cancer.
Of the whole patient material 263 patients
belonging to clinical stages I-III were analysed in
respect to disease-free interval. The mean follow-up
time was 41 months, and only patients followed-up
for more than 24 months were included. Eighty-
seven (30%) of patients were pre-menopausal and
199 (70%) postmenopausal. In 251 patients (88%) a
modified radical mastectomy was carried out, and a
Halsteds' radical mastectomy in 5 patients (2%).
Simple mastectomy with or without axillary node
sampling was performed in 24 patients (8%) and
other types of operations including modified radical
mastectomy and plastic reconstructions in 6 patients
(2%). Axillary node histology revealed metastases
in 142 patients (59%), and in 134 patients (47%)
axillary node histology was normal; in 10 patients
(3%) no axillary node biopsy was performed. Table
I shows the staging of our patients based on TNM
classification. As stated above, TNM classification
for axillary node status is based on histological
examination in all but 10 patients without axillary
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Table I TNM classification for
whole material
Patients
Stage n %
I 63 22
II 164 57
III 36 13
IV 23 8
Total 286 100
node biopsy. The mean tumour diameter was
32mm. Postoperative radiotherapy was given to
152 patients (54%). In 22 patients out of 263 (8.3%
) with stage III disease postoperative
chemotherapeutic or endocrine treatment was
carried out. Of these 22 patients adjuvant
chemotherapy was given to 17 patients (6.3%) and
adjuvant endocrine treatment to 5 patients (1.9%)
respectively.
All the patients were followed up at the
postmastectomy clinic at 3-month intervals up to 24
months, and subsequently at 6-month intervals.
Metastases were diagnosed in 83 patients and were
verified by fine-needle aspiration biopsy and/or
surgical biopsy, chest and bone radiography and/or
liver and brain scans. The dominant site of first
metastasis is presented in Table II.
Table II Dominant site of first metastases
Patients
Localisation n %
Soft tissue only 22 27
Bone and/or soft tissue 21 25
Visceral and/or bone
and/or soft tissue 40 48
Total 83 100
ER and PR assays
At operation, after the tumour had been removed,
it was immediately trimmed, and adjacent pieces
were taken for receptor determinations and
histopathological studies. The sample for receptor
studies was placed into a small plastic bag and
frozen in liquid nitrogen in the operating theatre.
The histopathological specimen was immediately
fixed with formalin.
Processing of the tissue specimen and
determinations of cytosol oestrogen and
progesterone receptors have been discussed in detail
elsewhere (Vihko et al., 1980). In short, cytosol
oestrogen receptor measurements were performed
using 7 different concentrations of tritiated
oestradiol as ligand, and non-labelled testosterone
was used to block the possible interference of sex
steroid binding globulin. Cytosol progesterone
receptors were measured using 7 different
concentrations of tritiated ORG 2058 as ligand. No
correction for the interference by plasma
contaminants was necessary since ORG 2058 does
not bind to any significant extent to plasma
proteins. Nonspecific binding of the tracer was
estimated from parallel sets of tubes which
contained a 100-fold molar excess of non-
radioactive oestradiol or ORG 2058 respectively.
After dextran-coated charcoal treatment and the
counting of the radioactivity, the results were
calculated by the method of Scatchard (Scatchard,
1949). The tumours were divided into "receptor
positive" and "receptor negative" categories. If the
ER or PR concentration was equal to or higher
than 10fmolmg-1 cytosol protein, the tumour was
classified as belonging to the former group,
otherwise to the latter.
Statistical methods
Patient groups with tumours of different ER and
PR contents were compared with respect to the
recurrence-free interval by the log rank test (Peto et
al., 1977). Statistical significance between curves
was assessed using both the generalized Wilcoxon
test and the Mantel-Cox procedure.
Results
Disease-free interval versus ER concentration
ER analyses from primary breast cancer tumours
showed ER positivity in 62.6% of all cases. The
mean concentration was 86fmolmg-1 cytosol
protein.
Comparisons as to duration of disease-free
interval were made between ER negativity and
positivity in the following groups: Stage I patients,
Stage II patients, Stage III patients, Stage
I+II+III patients (Figure 1), and also separately
between node-negative and node-positive patients
(Figure 2). There was no significant difference
between ER positive and negative patients with
regard to disease-free interval. Stage IV patients
were excluded, because these patients had primary
metastases. The possible relationship between ER.
concentration and the disease-free interval was
studied in 164 stage II patients (Figure 3), using ER
concentrations of 5, 10 and 20fmolmg-1 cytosol
protein as cut off-levels for receptor positivity.
Irrespective of receptor concentration levels there
were no differences between oestrogen receptor
positive and negative patients and the disease-free
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Figure 1 Oestrogen receptor status and disease-free interval in 263 patients, with Stage I, II or III breast
cancer.
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Figure 2 Oestrogen receptor status and disease-free
interval in 122 node positive and 131 node negative
breast cancer patients.
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Figure 3 The effect of oestrogen receptor positivity
level on disease-free interval in 164 Stage II breast
cancer patients.
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Figure 4 Progesterone receptor status and disease-free interval in 263 patients, with Stage I, II or III breast
cancer.
Disease-free interval versus PR concentration
PR positivity was recognized in 62.9% of all cases.
The mean PR concentration was 145fmolmg-1
cytosol protein. Comparisons as to duration of the
free interval with regard to progesterone receptor
positivity were made in the following groups: Stage
I patients, Stage II patients. Stage III patients,
Stage I + II +III patients (Figure 4), and also
separately between node negative and positive
patients (Figure 5). There were no significant
differences between PR positive and negative
patients with regard to disease-free interval.
The tumours of stage II patients were further
divided into the ER and PR positive category and
the ER and PR negative category. Metastasis
appearance in these two groups was compared after
a 24-month postoperative follow-up period using
X2-test. In the ER and PR receptor positive group
metastases were diagnosed in 21/68 patients (24%)
and in the ER and PR negative group in 20/55
patients (27%), respectively. The observed
difference was not significant.
Discussion
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Figure 5 Progesterone receptor status and disease-free
interval in 122 node positive and 131 node negative
breast cancer patients.
interval in our material consisting of 263 primary
breast cancer patients with stage I, II or III disease.
In this material adjuvant chemotherapy was given
to 6.5% and adjuvant endocrine treatment to only
1.9% of the 263 patients, these being patients with
stage III disease. Minimum follow-up time was 24
months. Receptor negativity versus positivity has
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been evaluated in the different stages I-III and in
node negative and node positive patients separately.
Our data on ER are in agreement with those of
Hilf et al. (1980), Kinne et al. (1981) & Howat et
al. (1983), who report that ER status of breast
cancer does not effect disease-free interval. In
contrast to this, Knight et al. (1977) first reported
that oestrogen receptor status was an independent
prognostic factor related to the recurrence of
primary breast cancer. This was soon confirmed by
other investigators (Furmanski et al., 1980;
Gapinski et al., 1980; Hartveit et al., 1980; Hahnel
et al., 1979; Leake et al., 1981; Lippman et al.,
1980; Westerberg et al., 1980). In most of the
studies cited the patients received some adjuvant
treatment, which could have an influence on the
results. In some, data concerning this detail were
not included. There are two reports with positive
correlation between ER status and disease-free
interval without adjuvant endocrine therapy
(Blamey et al., 1980; Osborne et al., 1980). A
positive correlation at the beginning of the follow-
up time has also been reported to disappear when
the follow-up time reaches 5 years (Furmanski et
al., 1980; Hiihnel et al., 1979).
There is little data concerning the prognostic
significance of PR status. In the papers of Saez et
al. (1983) and Clark et al. (1983). positive
correlations have been reported. We could not
show this in our material. Our result is in
agreement with the study of Griffiths et al. (1983)
and Howat et al. (1983).
Our data do not support the view that ER
and/or PR positivity would be associated with a
prolonged disease-free interval. The discordance
with a number of other studies strongly suggests
that adjuvant endocrine measures have an
important influence on disease-free interval in
primary breast carcinoma.
This investigation was supported by Finnish Cancer
Foundation.
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